🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Clinical Value of ETCOc in the Diagnosis and Treatment of ABO-HDN

Recruitingn/aAges any - 7 DaysAllWomen's Hospital School Of Medicine Zhejiang Univ…
NCT05842109 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

A prospective observational cohort study was designed. 1. Comparing of the clinical indicators between the hemolytic group and the non-hemolytic group,such as End-tidal carbon monoxide corrected for ambient CO(ETCOc),direct antiglobulin test(DAT), the highest total serum bilirubin level and hemoglobin. To explore the role of ETCOc in the diagnosis of neonatal ABO hemolytic disease. 2. Comparing of the clinical indicators between the neonates with IVIG treatment and the neonates without IVIG treatment in ABO hemolytic disease, such as ETCOc,total serum bilirubin level before IVIG treatment and ETCOc,total serum bilirubin level after IVIG treatment.To explore the clinical value of ETCOc in the treatment of ABO hemolytic disease.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * gestational age between 35+0 and 41+6 weeks * birth weight ≥ 2500 grams * respiratory rate \< 60 breaths per minute * the neonates admitted to the neonatology department for phototherapy because of hyperbilirubinemia that conforms to the guideline of the experts consensus on the management of neonatal hyperbilirubinemia(2014,in China.) * ABO group incompatibility between the mother and newborn * the informed consent are obtained. Exclusion Criteria: * persistent dyspnea or need for respiratory support * skin damage or structural deformity around the nasal cavity * receive intensive care treatment in the neonatal intensive care unit(NICU) * Severe congenital malformation, chromosomal or genetic abnormality
💊

What it tests

  • Not listed
📍

Where

1 site
Women's hospital School of medicine Zhejiang University
Hangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy